Cite
HARVARD Citation
Martin, T. et al. (2021). Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current medical research and opinion. pp. 1779-1788. [Online].